Non-small cell lung cancer

Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases. It is a type of cancer that starts in the cells that line the lungs and can spread to other parts of the body if not treated early.

Osimertinib for EGFR-Mutated NSCLC

The FLAURA trial has shown that osimertinib is an effective treatment option for patients with NSCLC and EGFR mutations. Mark A. Socinski, MD, discusses how the trial led to the adoption of osimertinib for these patients, improving their survival rates.

If you or a loved one has been diagnosed with NSCLC, it is important to speak with your healthcare provider about all available treatment options, including osimertinib for those with EGFR mutations.